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Abstract
Background: This study has attempted to assess the effectiveness of quantitative faecal immunochemical tests (FIT)
for triage of people presenting with lower abdominal symptoms, where a referral to secondary care for investigation of
suspected colorectal cancer (CRC) is being considered, particularly when the 2-week criteria are not met.
Methods: We conducted a systematic review following published guidelines for systematic reviews of diagnostic tests.
Twenty-one resources were searched up until March 2016. Summary estimates were calculated using a bivariate model
or a random-effects logistic regression model.
Results: Nine studies are included in this review. One additional study, included in our systematic review, was provided
as ‘academic in confidence’ and cannot be described herein.
When FIT was based on a single faecal sample and a cut-off of 10 μg Hb/g faeces, sensitivity estimates indicated that a
negative result using either the OC-Sensor or HM-JACKarc may be adequate to rule out nearly all CRC; the summary
estimate of sensitivity for the OC-Sensor was 92.1% (95% confidence interval, CI 86.9–95.3%), based on four studies
(n = 4091 participants, 176 with CRC), and the only study of HM-JACKarc to assess the 10 μg Hb/g faeces cut-off
(n = 507 participants, 11 with CRC) reported a sensitivity of 100% (95% CI 71.5–100%). The corresponding specificity
estimates were 85.8% (95% CI 78.3–91.0%) and 76.6% (95% CI 72.6–80.3%), respectively.
When the diagnostic criterion was changed to include lower grades of neoplasia, i.e. the target condition included
higher risk adenoma (HRA) as well as CRC, the rule-out performance of both FIT assays was reduced.
Conclusions: There is evidence to suggest that triage using FIT at a cut-off around 10 μg Hb/g faeces has the
potential to correctly rule out CRC and avoid colonoscopy in 75–80% of symptomatic patients.
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Background
Colorectal cancer (CRC) is the third most common can-
cer in the UK population overall and in people aged
50 years and over, after breast and lung cancer for
females and prostate and lung cancer for males. The
Office for National Statistics (ONS) cancer registration
data for 2013 showed approximately 35,000 new cases of
CRC in England (18,839 males and 14,926 females) [1].
CRC accounted for approximately 11.5% of all new can-
cers diagnosed in 2013 (12.6% in males and 10.4% in fe-
males) and increased with age to 14.2% of cancers in
males and 15.2% in females aged 80 years and over [1].
The UK has established bowel screening programmes
with colonoscopy being offered following a positive
faecal occult blood test using a guaiac test or qualitative
faecal immunochemical test (FIT). Screening is offered
to people between the ages of 60 and 74 years in
England, Wales and Northern Ireland, and between the
ages of 50 and 74 years in Scotland. Older people can
opt to continue screening. Despite efforts to promote
screening, the 2015 National Bowel Cancer Audit Report
stated that, of all patients diagnosed with CRC in 2014,
55% were diagnosed following a referral by a general
practitioner (GP), 9% (20% of those in the eligible age
range for screening) were diagnosed through the
National Health Service (NHS) Bowel Cancer Screening
Programme and 20% were only diagnosed following an
emergency presentation (referral source data were miss-
ing for 16% of patients) [2]. The Cancer Audit Report
recommended work to promote awareness of CRC
symptoms, as well as work to promote screening uptake;
however, increased awareness of symptoms and conse-
quent presentation in primary care could result in more
invasive investigations such as colonoscopy being re-
quired. Estimates from the charity Bowel Cancer UK [3]
have suggested that there will be a 10–15% year-on-year
increase in demand for colonoscopies, which would have
an impact on the 2-week suspected cancer referral time
applied in England and NHS capacity [4]. Colonoscopy
has associated risks which include bowel perforation,
bleeding and abdominal pain [5]; UK NHS audit data
have provided an estimated rate of complications (perfo-
rations and significant haemorrhages) of approximately
3 per 1000 colonoscopies [6]. A recent review reported
that most colonoscopies performed in symptomatic pa-
tients do not find either CRC or other serious bowel dis-
ease and do not result in changes to the treatment
approach [7]. The identification of tests which can help
to select those people with symptoms who are more
likely to benefit from further investigation is an import-
ant goal for optimal use of colonoscopy.
In addition to the 2-week wait referral criteria, the
2015 version of the National Institute for Health and
Care Excellence (NICE) guideline ‘Suspected cancer:
recognition and referral’ (NG12) recommended tests for
occult blood in faeces in adults without rectal bleeding
who are aged 50 years and over and have unexplained
abdominal pain or weight loss; are aged under 60 years
and have changes in their bowel habit or iron deficiency
anaemia; or are aged 60 years and over and have an-
aemia in the absence of iron deficiency [4]. These recom-
mendations were problematic in that they were widely
interpreted as a recommendation for a traditional guaiac
faecal occult blood test (gFOBT), a method which has
relatively poor sensitivity (approximately 75%) [8–10] in
symptomatic populations and which is no longer widely
available in the UK NHS, outside the screening pro-
grammes. The recommendations were also criticised for
not incorporating clinical judgement and hence potentially
leading to high numbers of inappropriate referrals, par-
ticularly in younger people [11, 12].
It has been suggested that using quantitative FIT to
select patients for referral has the potential to reduce un-
necessary colonoscopies and provide more accurate classi-
fication of patients than traditional, symptoms-based
guidelines [13]. FIT is recommended in European
Commission screening guidelines [14] and has now been
approved for use in the Scottish Bowel Screening
Programme, the NHS Bowel Cancer Screening
Programme in England and Bowel Screening Wales. It is
vital to remember that evidence about the performance of
FIT in asymptomatic population-based screening popula-
tions cannot be used to decide whether FIT should be rec-
ommended to inform referral decisions in people with
symptoms suggestive of lower gastrointestinal tract dis-
ease, particularly CRC. This is because the prevalence of
CRC may be higher in a population with low level symp-
toms than in the wider population who are eligible for
screening. Furthermore, FIT used for screening applica-
tions may be qualitative analyses or use higher cut-off fae-
cal haemoglobin concentrations than would be considered
appropriate for the triage of people with symptoms.
This systematic review analysed the clinical effective-
ness of FIT for triaging referrals in people with lower ab-
dominal symptoms, particularly those who would be
considered to be at low risk of having CRC. The review
was undertaken as part of a diagnostic appraisal to
inform the development of new NICE diagnostics guid-
ance (DG30) [15]. The appraisal also included the devel-
opment of a cost-effectiveness model, which is not
included in this article [16].
Methods
We conducted a systematic review with the main aim of
summarising the evidence about the effectiveness of quan-
titative FIT for triage of people presenting with lower ab-
dominal symptoms, where a referral to secondary care for
investigation of suspected CRC is being considered, but
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the 2-week criteria are not met. Systematic review
methods followed the principles outlined in the Handbook
for Diagnostic Test Accuracy Reviews [17], the Centre for
Reviews and Dissemination guidance for undertaking re-
views in health care [18] and the NICE Diagnostic Assess-
ment Programme manual [19].
Data sources
The following databases were searched from inception
to March 2016: MEDLINE; MEDLINE In-Process
Citations and Daily Update; MEDLINE Epub Ahead of
Print; Embase; Cochrane Database of Systematic
Reviews (CDSR); Cochrane Central Register of
Controlled Trials (CENTRAL); Database of Abstracts
of Reviews of Effects (DARE); Health Technology
Assessment (HTA) Database; NHS Economic
Evaluation Database (NHS EED); International Net-
work of Agencies for Health Technology Assessment
(INAHTA); National Institute for Health Research
(NIHR) Health Technology Assessment Programme;
Aggressive Research Intelligence Facility (ARIF); PROS-
PERO. We also searched clinical trials registers
(National Institutes of Health (NIH) ClinicalTrials.gov,
European Union (EU) Clinical Trials Register and
World Health Organization (WHO) International
Clinical Trials Registry Platform) and conference
proceedings (American Gastroenterological Associ-
ation, Digestive Disease Week (DDW), Annual Meeting
of the American Association for Clinical Chemistry and
Laboratory Medicine (AACC), British Society of
Gastroenterology (BSG) Annual Meeting, United
European Gastroenterology Week (UEGW) and the
European Congress of Clinical Chemistry and
Laboratory Medicine (IFCC-EFLM), 2011–2015).
Furthermore, we contacted experts in the field, with
the aim of identifying any unpublished studies. Search
strategies were based on index test (FIT assays) and
target condition (CRC) and did not include any study
design terms or filters [20]; example search strategies
are provided online (Additional file 1: Material S1). No
restrictions on language or publication status were
applied to any searches.
Inclusion criteria
Diagnostic cohort studies, which assessed the accuracy
of quantitative FIT assays in people with lower abdom-
inal symptoms who were being investigated for sus-
pected CRC, were eligible for inclusion.
We included studies where the participant selection
criteria were unclear, but where the population was de-
scribed as symptomatic/suspected CRC and no asymp-
tomatic participants were included. Where studies were
conducted in mixed populations (both symptomatic and
asymptomatic people included), study authors were
contacted to request separate data for the symptomatic
people sub-group. Studies conducted in people with pre-
existing gastrointestinal tract co-morbidities were
excluded.
Only clinical evaluations of the following quantitative
FIT assays, which are commercially available in the
UK, were included: OC-Sensor (Eiken Chemical Co.
Ltd, Tokyo, Japan, supplied in the UK by MAST Group
Ltd, Bootle, Merseyside); HM-JACKarc (Kyowa-Medex
Co. Ltd, Tokyo, Japan, supplied in the UK by Alpha La-
boratories Ltd, Eastleigh, Hants); FOB Gold (Sentinel
Diagnostics, Milan, Italy, supplied in the UK by
Sysmex UK Ltd, Milton Keynes); Ridascreen (R-Bio-
pharm AG, Darmstadt, Germany, supplied in the UK
by R-Biopharm Rhone Ltd, Glasgow).
Included studies were required to confirm diagnosis
using colonoscopy as the reference standard and to re-
port sufficient data to determine the numbers of true
positive (TP), false positive (FP), false negative (FN)
and true negative (TN) test results. Where studies re-
ported FIT uptake rates or test accuracy data for other
target conditions, in addition to CRC (e.g. adenoma,
particularly higher risk, inflammatory bowel disease,
organic bowel disease), we also included these data in
our review.
Studies were screened for relevance independently by
two reviewers, and full text articles of studies considered
potentially relevant were assessed for inclusion by one
reviewer and checked by a second. Disagreements, at
either stage of study selection, were resolved through
discussion and consensus, or by consultation with a
third reviewer.
Data extraction
One reviewer extracted data using a pre-study piloted
data extraction form, and the extractions were checked
by a second reviewer; any disagreements were resolved
through discussion and consensus or by consultation
with a third reviewer. Data were extracted on the fol-
lowing: study details, inclusion and exclusion criteria,
participant characteristics (demographic characteris-
tics, presenting symptoms, other CRC risk factors),
target condition (CRC, advanced neoplasia (higher risk
adenoma or CRC), other significant bowel disease out-
comes (as reported)), details of the FIT test (manufac-
turer, analyser used, definition of cut-off faecal
haemoglobin concentration (f-Hb), sampling proced-
ure, detection method), details of the reference stand-
ard, definitions of the target conditions, test
performance outcome measures (numbers of TP, FP,
FN and TN test results) and proportion of study par-
ticipants who returned a FIT sample (extracted as an
indicator of acceptability).
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Quality assessment
The methodological quality of included studies was
assessed using Quality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) [21], which uses four domains to as-
sess risk of bias and three domains to assess the applic-
ability of the study to the review question. Studies which
reported the diagnostic performance of a risk prediction
score that included FIT, in addition to measure of the ac-
curacy of FIT alone, were additionally assessed using the
prediction study risk of bias assessment tool (PROBAST)
[22]. Quality assessment was undertaken by one reviewer
and checked by a second reviewer, and any disagreements
were resolved by consensus or discussion with a third
reviewer.
Analysis
Sensitivity and specificity, with 95% confidence interval
(CI), were calculated for each set of 2 × 2 data. The bi-
variate/hierarchical summary receiver operating charac-
teristic (HSROC) model was used to estimate summary
sensitivity and specificity with 95% CI and prediction re-
gions around the summary points and to derive HSROC
curves for meta-analyses involving four or more studies
[23–25]. This approach allows for between-study hetero-
geneity in sensitivity and specificity and for the trade-off
(negative correlation) between sensitivity and specificity
commonly seen in diagnostic meta-analyses. For meta-
analyses with fewer than four studies, we estimated sep-
arate pooled estimates of sensitivity and specificity, using
random-effects logistic regression [26]. Heterogeneity
was assessed visually using summary ROC plots and sta-
tistically using the variance of logit (sensitivity) and logit
(specificity), where “logit” indicates the logistic function:
the smaller these values, the less heterogeneity between
studies. Analyses were performed in Stata 10 (StataCorp
LP, College Station, TX, USA), using the metandi com-
mand. For analyses that would not run in Stata, we used
Meta-DiSc [27].
Studies were grouped by FIT assay type, by target con-
dition and by cut-off f-Hb. Stratified results tables and
ROC space plots are presented to illustrate the variation
of test performance by cut-off f-Hb, and flow charts are
provided to illustrate the progress of a hypothetical co-
hort of patients through a diagnostic work-up that in-
cludes triage using FIT at the optimal cut-off.
Results
Overview of included studies
The searches identified 5782 references; nine studies, re-
ported in 26 publications [28–53], were included in our
review. A table detailing the primary and related publi-
cations, for each included study, is provided online
(Additional file 2: Table S1). One additional unpublished
study was provided by Sysmex UK Ltd (the supplier of
FOB Gold reagents for FIT assays in the UK, manufac-
tured by Sentinel Diagnostics, Milan, Italy). This study
was included in the version of our full report, which was
considered by the NICE Diagnostics Appraisal Commit-
tee when formulating guidance, but it cannot be in-
cluded in this article because it was provided as
‘academic in confidence’. Additional unpublished data
were supplied by the authors of two studies [33, 35].
Figure 1 shows the flow of studies through the review
process. Full details of the studies excluded after full
text analysis, with reasons for exclusion, are provided
online (Additional file 3: Table S2).
Five studies reported accuracy data for the OC-
Sensor FIT assay (Eiken Chemical Co. Ltd, Tokyo,
Japan); one used the io analyser [28], one used the
Diana automated immunoturbidimetric analyser [32],
two used the MICRO desktop analyser [29, 35] and
one did not report the analyser used [31]. Three stud-
ies reported accuracy data for the HM-JACKarc auto-
mated system (Kyowa Medex Co. Ltd, Tokyo, Japan)
[33, 34, 52]. The remaining two studies reported ac-
curacy data for the FOB Gold assay; one used the
Roche Modular P/917 analyser (Roche Diagnostics
Ltd, West Sussex, UK) [30], and the un-published
study, provided as ‘academic in confidence,’ and not
included here, used the SENTiFIT 270 analyser
(Sentinel Diagnostics, Milan, Italy). Five studies re-
ported receiving some funding from manufacturers
(including supply of test kits, reagents and analysers)
[31–34, 52], one study did not report details of fund-
ing [30] and the unpublished study was conducted at
the request of the test manufacturer. No studies were
identified which assessed the diagnostic performance
of RIDASCREEN Hb or RIDASCREEN Hb/Hp com-
plex in symptomatic patients.
Study quality
All studies included in this systematic review were diag-
nostic cohort studies (i.e. studies conducted in a group
of patients in whom the presence of the target condition
is suspected and which are therefore representative of
the setting in which the test would be used in practice);
diagnostic case-control studies (i.e. studies in which a
test is evaluated in healthy controls and people with a
previously established diagnosis of the target condition)
were excluded. The methodological quality of these
studies was assessed using the QUADAS-2 tool [21].
Two studies were reported only as conference abstracts,
with limited descriptions of methods [30, 52], and two
studies were rated as having ‘low’ risk of bias for all do-
mains [31, 34]. Three studies were rated as ‘high’ risk of
bias on the flow and timing domain [28, 32, 52], because
some patients who returned a sample for FIT (11–38%)
were subsequently excluded from the analyses. All of the
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included studies were rated as having ‘high’ concerns
about applicability to the specific research aim with re-
spect to participants. This happened because all studies
included some participants who had symptoms that may
be considered to be associated with a higher probability
of CRC and which are components of the criteria for 2-
week referral as defined in NG12 [4] (e.g. rectal bleed-
ing). In addition, only one study was conducted in a
primary care setting, reporting that FIT was requested
by GPs at the point of referral to secondary care [28].
The results of the QUADAS-2 assessment are sum-
marised in Table 1, and full details of the participant
characteristics, FIT assay and reference standard for
each study are provided online (Additional file 4:
Table S3). PROBAST assessments for the two studies
that reported the development and validation of risk
prediction scores [29, 50] are provided online (web-
Additional file 5: Table S4).
Fig. 1 Flow of studies through the review process
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Diagnostic performance of the OC-Sensor FIT assay
All five studies that evaluated the OC-Sensor assay
reported accuracy data, where CRC was the specified
target condition [28, 29, 31, 32, 35]. The prevalence of
CRC, diagnosed at colonoscopy, in these studies ranged
from 2.1 to 12.3%. Four studies [28, 29, 31, 32] also
reported data for the composite target condition of
advanced neoplasia (AN) defined as CRC or higher risk
adenoma (HRA), or CRC or advanced adenoma; where a
definition was provided, an HRA was defined as an
adenoma ≥ 10 mm in diameter or three or more aden-
omas of any size: advanced adenomas were considered
as adenomas > 10 mm in diameter or adenomas with
villous architecture or high grade dysplasia [29, 31].
Three studies reported additional accuracy data on
various non-malignant and composite target conditions
[28, 32, 35]. Accuracy data, for all target conditions and
cut-offs evaluated, are summarised in Table 2, and ac-
curacy data for CRC at all f-Hb cut-offs evaluated are
summarised in Fig. 2.
The optimal test performance (maximising both sensi-
tivity and specificity) appeared to occur with f-Hb cut-
offs of 10 or 15 μg Hb/g faeces, with most data being
available for the 10 μg Hb/g faeces cut-off. The summary
estimates of sensitivity and specificity, using the 10 μg
Hb/g faeces cut-off, were 92.1% (95% CI 86.9–95.3%)
and 85.8% (95% CI 78.3–91.0%), respectively, based on
data from four studies [28, 29, 32, 35]. Figure 3 shows
the HSROC for the OC-Sensor assay, using the 10 μg
Hb/g faeces cut-off, based on these four studies. As can
be seen from Fig. 3 and Table 2, between-study hetero-
geneity was greater for specificity values than for sensi-
tivity values; the coefficient of variance of logit
sensitivity was 0.0002362 (standard error 0.0145951) and
the coefficient of variance of logit specificity was
0.2577195 (standard error 0.2096304).
Three studies reported separate accuracy data, using
the 10 μg Hb/g faeces cut-off, for both CRC and the
composite target condition AN [28, 29, 32]. The
prevalence of CRC across these studies was 3.1%. Using
test performance data from these three studies, and a
CRC prevalence estimate of 3.1% to consider the out-
come of testing for a hypothetical cohort of 1000 pa-
tients, the results indicate that, using the 10 μg Hb/g
faeces cut-off, two CRCs would be missed and 179 un-
necessary colonoscopies would be carried out (assuming
that all patients with a positive FIT result receive colon-
oscopy and that all colonoscopies conducted in patients
without CRC are considered unnecessary). CRC would
be correctly ruled out by FIT, avoiding colonoscopy, in
789 of the 1000 patients (Fig. 4a). Expanding the target
condition from CRC only to AN resulted in an increase
in prevalence from 3.1 to 11.3% [28, 29, 32]. If the 10 μg
Hb/g faeces cut-off were applied to the expanded target
condition, for the hypothetical cohort of 1000 patients,
the number of missed cases would increase from 2 to 42
(2 CRC and 40 HRA); using this cut-off, 137 unneces-
sary colonoscopies would be carried out and AN would
be correctly ruled out in 749 of the 1000 patients
(Fig. 4b). Approximately 22% of those classified as hav-
ing a false positive FIT result for CRC would have HRA
identified at colonoscopy. One study [28] evaluated the
diagnostic performance of OC-Sensor (10 μg Hb/g fae-
ces threshold) for a further composite target condition
that included CRC and HRA plus inflammatory bowel
disease (IBD). Results from this study (Table 2) indicate
that 45 of the 151 participants (29.8%) who were classi-
fied as having false positive FIT results for CRC actually
had other significant bowel pathology (HRA or IBD) and
may thus have benefitted from secondary care
investigation.
One of the three studies described above also conducted
multivariable analysis, using forward conditional logistic
regression modelling, with the aim of identifying inde-
pendent predictors of CRC and AN [29]. The CRC ana-
lysis identified male gender (odds ratio, OR 2.39 (95% CI
1.039–5.519), p = 0.041), iron deficiency anaemia (OR 2.99
(95% CI 1.27–7.03), p = 0.012) and f-Hb ≥ 10 μg Hb/g
Table 1 QUADAS-2 results for studies of FIT assays
Study Risk of bias Applicability concerns
Patient selection Index test Reference standard Flow and timing Patient Index test Reference standard
Auge 2016 [34] Low Low Low Low High Low Low
Cubiella 2014 [31] Low Low Low Low High Low Low
Godber 2016 [33] Low Low Unclear Low High Low Low
Krivec 2011 [30] Unclear High Unclear Unclear High Low High
McDonald 2013 [32] Low Low Unclear High High Low Unclear
Mowat 2015 [28] Low Low Low High High Low Low
Rodríguez-Alonso 2015 [29] Unclear Low Low Low High Low Low
Terhaar sive Droste 2011 [35] Low Low Low Unclear High Low Low
Thomas 2016 [52] Unclear Low Unclear High High Low Low
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faeces (OR 86.60 (95% CI 11.70–641.16), p < 0.001) as in-
dependent predictors [29]. The AN analysis identified
male gender (OR 2.36 (95% CI 1.50–3.40), p < 0.001), age
(OR 1.36 (95% CI 1.13–1.63), p < 0.001) and f-Hb ≥ 10 μg
Hb/g faeces (OR 7.54 (95% CI 5.03–11.28), p < 0.001) as
independent predictors; age was treated as a categorical
variable in this model (≤40 years, 41–60 years, 51–60
years, 61–70 years, ≥ 70 years) [29]. The results of model-
ling were used to derive a risk score for AN; the scoring
system assigned integer values to each independent pre-
dictor based on their coefficients from the logistic regres-
sion model [29]. The score ranged from 0 to 11 with
points assigned as follows: age < 40 years = 0 points, age
41 to 50 years = 1, age 51 to 60 years = 2, age 61 to
70 years = 3, age > 70 years = 4; female gender = 0, male
gender = 2; f-Hb < 10 μg Hb/g faeces = 0, f-Hb ≥ 10 μg
Hb/g faeces = 5 [29]. The model was validated using a split
sampling technique (data from 680 study participants
(67.8%) were used to develop the model and data from
323 participants (32.2%) were used for validation) [29]. In
the validation sample, a risk score ≥ 5 had a sensitivity for
AN of 88.1% (95% CI 74.3–96.0%) and a specificity of
63.3% (95% CI 57.4–69.0%) [29]. We identified a second
risk score for CRC in symptomatic patients, based on FIT
age and sex (the Faecal haemoglobin, Age and Sex Test
(FAST) score) [53], which was developed as a simplifica-
tion of the COLONPREDICT model approach [50]. The
logistic regression model used to develop the FAST score
included gender, age as a continuous variable and f-Hb as
a categorical variable (0, 0 to < 20, 20 to 200, and ≥ 200 μg
Hb/g faeces [53]. The validation cohort for this model
used data from five studies included in this systematic
review [28, 29, 32, 33, 50], incorporating data from a num-
ber of FIT assays, including OC-Sensor and HM-
JACKarc [28, 29, 32, 33], and an additional cohort
recruited to the COLONPREDICT study between
March 2014 and March 2015 [50]. The example FAST
score cut-offs used to assess the performance in the
validation cohort corresponded to the beta coefficients
of the FAST score with 90% and 99% sensitivity in the
development cohort (4.50 and 2.12, respectively. In
the validation cohort, a FAST score of ≥ 4.50 had a
sensitivity of 89.3% (95% CI 84.1–93.0%) and a speci-
ficity of 82.3% (95% CI 81.1–83.5%) for CRC. In order
to avoid missing any CRC, a lower FAST score cut-
off of ≥ 2.12 was required; the sensitivity and specifi-
city estimates at this cut-off were 100% (95% CI
97.7–100%) and 19.8% (95% CI 18.6–21.1%), respect-
ively, for CRC and 96.7% (95% CI 94.9–98.0%) and
21.5% (95% CI 20.1–22.9%) for AN [50].
Four studies reported information about uptake
rates in participants invited to provide a sample for
FIT [28, 29, 31, 32]. The proportion of people in-
vited to participate in FIT who return a faecal sam-
ple can be regarded as a possible indicator of the
acceptability of the test; however, the context in
which patients were asked to provide a sample for
FIT was also considered to be a key factor influen-
cing uptake. Reported uptake rates for the OC-
Sensor studies included in our review varied widely,
ranging from 41% (in a study where patients were
sent an invitation to participate along with their re-
ferral letter [32]) to 98% (in a study where patients
were given the specimen collection device at their
initial consultation with a gastroenterologist [29]): it
is important to recognise that neither study was
Fig. 2 ROC space plot for the OC-Sensor assay using different faecal
haemoglobin cut-offs for the target condition of CRC
0
.2
.4
.6
.8
1
0.2.4.6.81
Specificity
Study estimate Summary point
HSROC curve 95% confidenceregion
95% prediction
region
Fig. 3 HSROC for the OC-Sensor assay using a 10 μg Hb/g faeces
cut-off and a single sample (four studies)
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done in a primary care setting in which a GP would
discuss the investigation with the patient and give a
specimen collection device and associated literature
at this time of consultation.
Diagnostic performance of the HM-JACKarc FIT assay
Two of the three studies that evaluated the HM-JACKarc
assay reported accuracy data, where CRC was the specified
target condition [33, 52]. The prevalence of CRC diagnosed
at colonoscopy in these studies was 2.2% [33] and 4.7%
[52]. Only one study [33] also reported data for the com-
posite target condition of AN (CRC or HRA). Two studies
reported additional accuracy data for various non-
malignant and composite target conditions [33, 52].
Accuracy data, for all target conditions and f-Hb cut-
offs evaluated, are summarised in Table 3.
The optimal test performance (maximising both sensi-
tivity and specificity) appeared to occur at the f-Hb cut-
off of 10 μg Hb/g faeces. The estimates of sensitivity and
specificity at this cut-off, derived from a single study,
were 100% (95% CI 71.5–100%) and 76.6% (95% CI
72.6–80.3%), respectively [33]. Using accuracy and
prevalence data from this study and the 10 μg Hb/g fae-
ces cut-off to consider the outcome of testing for a
hypothetical cohort of 1000 patients indicates that no
CRC would be missed, but 229 unnecessary colonos-
copies would be carried out (assuming that all patients
with a positive FIT result receive a colonoscopy and that
all colonoscopies conducted in patients without CRC are
considered unnecessary); CRC would be correctly ruled
out by FIT, avoiding colonoscopy, in 749 of the 1000 pa-
tients (Fig. 5a). Expanding the target condition from
CRC only, to include CRC or HRA, resulted in an in-
crease in prevalence from 2.2 to 5.9% [33]. If the 10 μg
Hb/g faeces cut-off were applied to the expanded target
condition, for the hypothetical cohort of 1000 patients,
22 cases of HRA would be missed, 205 unnecessary col-
onoscopies would be carried out and CRC and HRA
would be correctly ruled out in 727 patients (Fig. 5b).
Approximately 10% of those classified as having a false
positive FIT result for CRC would have HRA identified
at colonoscopy and a further 10% would be diagnosed
with other significant bowel disease (IBD or colitis
(Table 3)) [33]. Data from one study [34] indicated that
the sensitivity of HM-JACKarc for AN was higher in
men than in women and when the highest value from
two consecutive faecal samples was used compared to
using only the first sample; full results are provided on-
line (Additional file 6: Table S5).
Two studies reported information about uptake
rates in participants invited to provide a sample for
FIT [33, 52]. The proportion of samples returned was
higher (66%) in the study where information and col-
lection devices were provided at an outpatient ap-
pointment [52] than in the study which sent collection
devices and information by post (56%) [33].
a
b
Fig. 4 Testing outcomes for a hypothetical cohort of 1000 patients using OC-Sensor at the 10 μg Hb/g faeces threshold, for the target condition
a CRC and b AN
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Diagnostic performance of the FOB Gold FIT assay
One study, reported in a conference abstract, assessed the
performance of the FOB Gold FIT assay in symptomatic
patients [30]. This study only reported data for the
composite target condition of significant bowel dis-
ease, defined as cancer, polyps or bleeding; sensitivity
and specificity were reported as 45.2% and 92.3%,
using an f-Hb cut-off of 9 μg Hb/g faeces [30]. Insuf-
ficient information was provided to allow calculation
of confidence intervals and 2 × 2 data. The unpub-
lished study provided by Sysmex UK Ltd was consid-
ered by the NICE Diagnostics Appraisal Committee,
when formulating the published recommendations,
which include the FOB Gold assay [16].
Discussion
Statement of principal findings
All studies included in our systematic review were
diagnostic cohort studies reporting accuracy data.
When FIT was based on a single faecal sample and
an f-Hb cut-off of 10 μg Hb/g faeces, sensitivity
estimates indicated that a negative result using either
the OC-Sensor or HM-JACKarc may be considered ad-
equate to rule out most CRC. The summary estimate of
sensitivity for the OC-Sensor was 92.1% (95% CI 86.9–
95.3%), based on four studies [28, 29, 32, 35], and the
negative predictive value varied between 99.4 and 100%
across these studies. The only study of HM-JACKarc to
assess the 10 μg Hb/g faeces cut-off reported a sensi-
tivity of 100% (95% CI 71.5–100%). Where a lower
diagnostic threshold was considered, i.e. the target
condition included HRA as well as CRC, the rule-out
performance of both FIT methods was reduced.
Evidence suggests that risk scores may have the po-
tential to provide a more reliable rule-out method
than FIT alone at lower thresholds of disease, but
that this is achieved at the cost of very poor specifi-
city [50, 53]. Triage using FIT at an f-Hb cut-off of
10 μg Hb/g faeces has the potential to correctly rule
out most CRC and avoid colonoscopy in 75–80% of
symptomatic adults. In addition, the apparent
relatively high number of FIT false positive results
observed when the target condition is CRC may be
mitigated by the detection of other bowel pathology
in these patients. Because all of the included studies
were conducted in patients for whom a referral to
secondary care had already been made or was being
considered, these estimates of the triage performance
of FIT can be considered to have incorporated the
judgement of primary care clinicians. The full poten-
tial benefits of FIT in symptomatic patients, includ-
ing those relating to diagnoses other than CRC,
remain unclear. This issue may be particularly im-
portant in younger patients, where the prevalence of
CRC is lowest and other diagnoses, particularly IBD,
are more likely.
a
b
Fig. 5 Testing outcomes for a hypothetical cohort of 1000 patients using HM-JACKarc at the 10 μg Hb/g faeces threshold, for the target condition
a CRC and b AN
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Strengths and weaknesses of study
Our study followed rigorous systematic review method-
ology, and our findings have informed the development of
up-to-date guidance. The new NICE DG30 diagnostic
guidance, now published, states: ‘The OC Sensor, HM-
JACKarc and FOB Gold quantitative faecal immunochem-
ical tests are recommended for adoption in primary care
to guide referral for suspected colorectal cancer in people
without rectal bleeding who have unexplained symptoms
but do not meet the criteria for a suspected cancer path-
way referral’ [15]. Limitations of our review include a lack
of studies directly comparing the performance of different
FIT assays; thus, all data included in our assessment de-
scribes the clinical effectiveness of individual FIT methods
and not their comparative effectiveness. Three of the ten
studies included in our systematic review were rated as
‘high’ risk of bias on the flow and timing domain, because
some patients who returned a sample for FIT (11–38%)
were subsequently excluded from the analyses. However,
we note that the main issue with respect to study quality
was the fact that no study reported data totally specific to
the low risk, symptomatic population defined in the 2015
version of the NICE guideline for suspected cancer recog-
nition and referral (NG12) [4]; all studies included some
participants who had symptoms (e.g. rectal bleeding) that
are considered to be associated with a higher probability
of CRC and are components of the current criteria for 2-
week wait suspected cancer referral. The prevalence of
CRC is likely to differ between populations with different
presenting symptoms, and it is well known that the preva-
lence of the target condition can affect estimates of test
performance [54]. The median prevalence of CRC in those
studies included in our review, which used the optimal f-
Hb cut-off of 10 μg Hb/g faeces, was 3.7% (range 2.1–
5.4%), compared to the estimate of 1.5% for the relevant
symptomatic group used in NG12 [55]. There is insuffi-
cient information to determine whether this difference
will affect the performance of FIT in primary care. How-
ever, it could be argued that the patients included in the
studies in our review are representative of those for whom
FIT would be useful in practice, irrespective of existing re-
ferral guidelines. A comparison of FIT to the NICE 2-
week wait referral criteria was outside the scope of our
study; however, two of the studies included in our system-
atic review did consider this issue [29, 50]. These studies
reported the development and validation of risk prediction
models for CRC [48] and AN [29]; f-Hb was identified as
an independent predictor in both, and in both cases the
final model demonstrated improved rule-out performance
compared to the NICE 2-week wait referral criteria. The
score based on the AN model had an optimum sensitivity
of 88.1% (95% CI 74.3–96.0%) compared to 38.3% (95% CI
30.0–47.2%) for the NICE criteria [29]. This study also re-
ported data indicating that FIT alone, at the f-Hb cut-off
of 10 μg Hb/g faeces, could offer improved rule-out per-
formance for CRC compared to the NICE 2-week wait re-
ferral criteria; the sensitivity estimate for FIT was 96.7%
(95% CI 82.2– 99.9%), compared to 46.7% (28.3–65.7%)
for the NICE criteria [29]. The FAST score had an optimal
sensitivity of 99.5% (97.0–100%) compared to 68.2% (95%
CI 61.5–74.3%) for the NICE referral criteria [50].
Strengths and weaknesses in relation to other studies
Systematic reviews have previously been conducted
which assessed the performance of various FIT assays
in screening settings [56, 57]. However, given the po-
tential for target condition prevalence to affect esti-
mates of test performance [54], it is important to
determine the diagnostic accuracy of FIT in the popu-
lation of interest. We identified one large systematic
review which assessed the value of symptoms and
additional diagnostic tests for CRC, used in symptom-
atic patients in primary care [58]. However, the
searches for this review were completed in 2008, and
it included only three studies of quantitative FIT as-
says which examined asymptomatic people as well as
symptomatic patients. Our systematic review is the
first to assess the performance of quantitative FIT as
a triage test in patients with symptoms and to con-
sider the potential utility of applying FIT as part of a
simple risk score.
Unanswered questions and future research
Population data indicate that f-Hb varies with age and sex,
being higher in men and the elderly [59, 60]. Further, a re-
cent study conducted in Scotland found that f-Hb also in-
creased with increasing levels of deprivation (measured
using the Scottish Index of Multiple Deprivation), and that
this trend remained after controlling for age and sex [61].
Thus, at any f-Hb cut-off, more men, more older people
and more people in high deprivation groups are likely to
have a positive result on FIT testing. The findings on
deprivation have been confirmed in a recent study per-
formed in England [62]. We did not identify any sub-
group test performance data for the target condition CRC;
however, one of the studies included in our systematic re-
view compared the accuracy of a FIT assay (HM-JACKarc)
in men and women [34] for the target condition AN. This
study found that, at all f-Hb cut-offs, the observed sensi-
tivity of HM-JACKarc was higher in men than in women
and the observed specificity was similar for men and
women [34]. This indicates that, at any given f-Hb cut-off,
more women than men with CRC or HRA may be missed
by using FIT as a triage test to determine referral to sec-
ondary care. Validation data for the FAST Score [50] indi-
cated that there were no significant differences in the
sensitivity of this tool between men and women, patients
under 50 years of age and those who were 50 years or over
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and FIT analytical system used. More data are needed to
adequately assess whether there are clinically relevant dif-
ferences in test performance between men and women
and between other clinically relevant sub-groups: such
data are needed for all FIT assays.
The effects on FIT performance of using multiple fae-
cal samples per patient remain unclear. One study [34]
included in our systematic review compared single ver-
sus double sampling and asked patients to collect two
consecutive faecal samples. This study reported that sen-
sitivity for AN was increased (at all f-Hb cut-offs) when
the highest value from two consecutive samples was
used, compared to using only the first sample; FIT re-
sults were discordant in 39.2% of participants [34].
There is currently insufficient information about intra-
individual variation in f-Hb over time to determine the
clinical utility of multiple sampling.
The scope of our systematic review did not include
evaluation of the performance characteristics of FIT
when used in combination with other biomarkers. Two
of the studies in our systematic review did compare FIT
and calprotectin assays for detection of significant bowel
disease and concluded that FIT alone had better rule-out
performance [28, 52]. Combination testing, where a
positive result was defined as both tests positive, pro-
vided increased specificity [52]. FIT, at an f-Hb cut-off of
7 μg Hb/g faeces, combined with faecal calprotectin, at a
cut-off of 50 μg/g faeces, had sensitivity, specificity and
negative predictive value (NPV) values of 69.6% (95% CI
50.8–88.4%), 92.5% (95% CI 90.0–95.0%) and 98.3%
(97.0–99.5%), compared to 91.3% (79.8–100%), 79.2%
(75.3–83.0%) and 99.4% (98.6–100%) for FIT alone [52].
However, where a positive result was defined as either
test positive, the addition of faecal calprotectin to FIT
offered no advantages [28]. The sensitivity, specificity
and NPV values for any detectable f-Hb or faecal calpro-
tectin ≥ 50 μg/g faeces were 100%, 23.3% and 100% com-
pared to 100%, 43.4% and 100% for any detectable f-Hb.
Following the evaluation reported here and the promul-
gation of the draft guidance from NICE [16, 63], a peer-
reviewed publication on the performance of the HM-
JACKarc [64] on 430 patients expanded on the preced-
ing study [52]. The additional data confirmed that FIT at
an f-Hb cut-off of 7 μg Hb/g faeces is sufficiently sensi-
tive to exclude most CRC, with higher values in left-
sided lesions. Faecal calprotectin in combination did not
appear to provide additional diagnostic information [52].
In contrast, we identified one further study which did
not meet the inclusion criteria for our systematic review
because it used a FIT assay unavailable in the UK and
Europe, but which reported data on the performance
characteristics of FIT in combination with faecal cal-
protectin, M2-PK or both (where a positive result was
defined as at least one test positive) for the target
conditions CRC and HRA, as well as data on the per-
formance characteristics of FIT alone [65]. Faecal cal-
protectin is an inflammatory marker, whilst M2-PK is a
key enzyme in tumour metabolism [65]. This study
found that, in all cases, the addition of at least one fur-
ther test to FIT resulted in markedly increased sensitiv-
ity and decreased specificity. The sensitivity and
specificity estimates for FIT alone and CRC were 61.7%
(95% CI 47.4– 74.2%) and 88.8% (95% CI 84.1–92.3%);
for the combination of FIT and faecal calprotectin these
estimates were 90.9% (95% CI 78.8–96.4%) and 35.9%
(95% CI 29.7–42.6%), for FIT and M2-PK, sensitivity
and specificity were 91.5% (95% CI 80.1–96.6%) and
57.1% (95% CI 50.6–63.2%) and for all three markers
they were 95.7% (85.7–98.8%) and 24.1% (18.8–30.2%)
[65]. Although all sensitivity estimates were generally
lower, this pattern was repeated where the target condi-
tion was AN [65]. A second study also found that combin-
ing faecal calprotectin with FIT (where a positive result
was defined as either or both tests positive) resulted in in-
creased sensitivity and decreased specificity for AN (92%
(95% CI 82–97%) and 49% (95% CI 43–54%)) compared
to FIT alone (74% (95% CI 62–83%) and 82% (95% CI 78–
86%)) [66]. This study did not meet the inclusion criteria
for this assessment because it used a qualitative FIT
method. The effectiveness of combining other biomarkers
with quantitative FIT (at the f-Hb cut-off at which FIT is
likely to be used in practice) remains unclear.
Conclusions
Implications for clinicians and policy makers
There is evidence to suggest that triage using OC-Sensor
or HM-JACKarc FIT, at an f-Hb cut-off of 10 μg Hb/g
faeces, has the potential to correctly rule out CRC and
avoid colonoscopy in 75–80% of symptomatic patients.
The relatively high proportion of FIT false positive re-
sults observed when the target condition is CRC may be
mitigated by the potential to detect other bowel path-
ology in these patients. However, the importance of clin-
ical judgement cannot be overemphasised. All of the
studies included in this review were conducted in symp-
tomatic populations selected on the basis of a GP’s
intention to refer rather than on the presence of a spe-
cific set of symptoms alone; overuse of FIT or blanket
referral following a positive result has the potential to
overwhelm colonoscopy services. There are currently no
data on the comparative performance of different FIT as-
says in this population. Given the trade-off between ease
of use/simplicity and diagnostic performance, the clinical
value of using additional variables (e.g. symptoms and
further diagnostic tests) to develop risk scores for CRC
and/or other significant bowel disease is likely to require
further investigation.
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What this paper adds
What is already known on this subject
The NICE guideline on suspected cancer recognition and referral (NG12)
recommends testing for occult blood in faeces for patients with
specified symptoms associated with a ‘low risk’ of bowel cancer.
This guideline has been widely interpreted as a recommendation for guaiac
faecal occult blood tests and it does not include any statements about the
importance of clinical judgement in deciding when to test in this population.
Faecal immunochemical testing has been approved for use in the
Scottish Bowel Screening Programme, the NHS Bowel Cancer Screening
Programme in England and Bowel Screening Wales, and existing
systematic review evidence supports this.
What this study adds
Triage using quantitative FIT, at a faecal haemoglobin concentration
cut-off of 10 μg Hb/g faeces, has the potential to avoid colonoscopy in
75–80% of symptomatic patients for whom a general practitioner is
considering a referral to secondary care, but who do not meet the
criteria for 2-week wait suspected cancer referral.
Secondary care referral following a positive FIT may facilitate the
identification of other significant bowel pathology in patients who are
found not to have lower gastrointestinal tract cancer.
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